Literature DB >> 28134688

Progress with treating the microbial dysbiosis associated with irritable bowel syndrome.

James S Pearson1, Peter J Whorwell.   

Abstract

PURPOSE OF REVIEW: Microbial dysbiosis is receiving increasing attention as possibly being important in the pathophysiology of irritable bowel syndrome. This review will summarize the most recent literature addressing attempts to explore and target the microbiome in patients with irritable bowel syndrome. RECENT
FINDINGS: Manipulation of the intestinal microbiota in irritable bowel syndrome is receiving increasing attention. Traditionally, dietary manipulation has been utilized. There is now evidence that a low fermentable oligosaccharides, disaccharides, monosaccharides and polyols diet has not only been able to improve symptoms, but may have an effect on the gut microbiota. Probiotics are a safe and attractive option for the manipulation of the microbiota. There have been a number of well-designed trials examining the efficacy of certain strains of bacteria, and even yeasts are receiving attention. The role of antibiotics remains controversial and it seems likely that their use should currently be limited to those individuals with small intestinal bacterial overgrowth. Interest in the role of faecal microbiota transplantation for the treatment of a number of gastrointestinal conditions has intensified and irritable bowel syndrome is no exception.
SUMMARY: The manipulation of the microbial dysbiosis is gaining momentum. Further research, however, is required in order to identify the most appropriate treatment option for each individual patient.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28134688     DOI: 10.1097/MOG.0000000000000328

Source DB:  PubMed          Journal:  Curr Opin Gastroenterol        ISSN: 0267-1379            Impact factor:   3.287


  1 in total

1.  Daily intake of broccoli sprouts normalizes bowel habits in human healthy subjects.

Authors:  Akinori Yanaka
Journal:  J Clin Biochem Nutr       Date:  2017-11-03       Impact factor: 3.114

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.